Reduced Research & Development (R&D) productivity, as well as patent expiries and advances in technology, has led to significant changes for the pharmaceutical industry. Leading life sciences firms are not only being forced to look closely at the scale and cost of their property portfolios but also question whether they are located in the best environment to access innovation and talent. Real estate in the life science industry is moving from being an operational necessity to a source of competitive advantage.
We all have a gut microbiome: a population of bacteria that lives in harmony with our body and provides a vital role in assisting our immune system to protect our body from harmful pathogens. An individual’s microbiome is unique, much like a fingerprint. Only now are we beginning to understand the importance and extent of the roles that this plays in all aspects of our health – from gut health to the more recently discovered impacts on the gut-brain axis and how this can mediate feelings of anxiety and depression.
The market for new antibiotics is effectively failing. No novel class of drugs for the most virulent and persistent infections, those caused by Gram negative bacteria, has entered the clinic for over 50 years, and the drugs we have are steadily, if slowly, becoming less effective. Earlier this year Dame Sally Davies, the outgoing Chief Medical Officer for England, described the threat of antibiotic resistance as ‘catastrophic’ and potentially as great as that from climate change.
BI (Business Intelligence) is a set of processes, architectures, and technologies that convert raw data into meaningful information that drives profitable business actions. It is a suite of software and services to transform data into actionable intelligence and knowledge.
Cambridge Antibody Technology has been described as the ‘jewel in the crown’ of the UK biotech industry; it is certainly one of our region’s principal success stories. This company, originally known as CAT, was founded in 1989 to take advantage of phage display technology for the development of antibody therapeutics. Following worldwide success with the blockbuster anti-TNF antibody adalimumab (Humira™) it was acquired by AstraZeneca in 2006 and now forms part of that company’s biologics subsidiary.
When it comes to influencing prospective customers in the life science sector, outbound marketing approaches such as cold calling, banner ads and unsolicited emails are no longer delivering a return on investment like they used to. Poorly targeted and relatively expensive, these once tried-and-tested tactics are increasingly delivering disappointing results. As marketers, if we want to continue to engage with modern scientific audiences, it’s vital that we adapt to be successful.
Whatsapp, Youtube, Google Ads, Linkedin, Facebook, Instagram, Twitter, e-mail, Teams, Skype, Slack… it’s easy to feel the dread and anxiety when glancing at your phone on an afternoon! All these platforms have one thing in common: your attention!
Even scientific brands have now joined the incessant competition for your attention. So how do you separate the signal from the noise in this increasingly competitive world?
Disaster can strike at any moment, but where do you start to put things right when the worst happens and fire ravages your priceless research, expensive equipment and impacts thousands of your patients who depend on the lab work for life-saving medical treatment?